The MarketWatch News Department was not involved in the creation of this content. -- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to ...
- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway “Dysregulated activation of the complement ...
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results